Open access · CC-BY
via OpenAlex
Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial
Mijra Koning, Artemiy Kovynev, Marcos F. Fondevila, Eliza J. M. Ruhé, Michiel C. Mommersteeg, Christian R. B. Ramakers, Barbara A. Hutten, Bart J. Verwer, Marije S. Vlug, Teaco Kuiper, Maarten W. Van Den Berg, Anne Vrieze, Maurice B. Bizino, Annewieke W. van den Beld, Luuk Berk
Nature Metabolism · 2026
Abstract
Cellular senescence(definition) plays an important role in hepatic inflammation and fibrosis1–3. However, whether senescence represents a potential therapeutic target in humans with metabolic dysfunction-associated steatohepatitis (MASH) remains unexplored. Here we report the results of a phase-2, double-blind, randomized, placebo-controlled trial of intermittent senolytic therapy with dasatinib plus quercetin (D + Q) in participants with fibrotic MASH. Thirty-one participants (median age 56 years; 76% male; 58% with type 2 diabetes) were randomized (1:1) to receive D + Q (dasatinib 100 mg per day plus quercetin 1,000 mg per day) or placebo for three consecutive days per week over 3 weeks, repeated across three 7-week cycles. The primary endpoint, ≥1 stage fibrosis improvement without MASH worsening on paired liver biopsies, is achieved in 47% of D + Q-treated participants versus 7% with placebo (P = 0.02). MASH resolution occurs more frequently with D + Q than placebo (53% versus 7%; P = 0.02), with a greater reduction in NAFLD Activity Score (−1.43 ± 1.22 versus −0.39 ± 0.77; P = 0.012). Single-nucleus RNA sequencing demonstrates decreased senescence and fibrotic gene signatures and reduced fibrogenic cell populations in the D + Q group. Although adverse events are more frequent in the D + Q group (82% versus 43%), these are all self-limiting. Overall, this proof-of-principle trial supports the need for future trials of senolytic therapy in fibrotic MASH. ClinicalTrials.gov identifier: NCT05506488 . In a double-blind, placebo-controlled trial, intermittent dasatinib and quercetin treatment over 21 weeks improves liver fibrosis in patients with MASH, as shown by paired liver biopsies, and reduces senescence and fibrotic gene signatures, as demonstrated by single-nucleus transcriptomics.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/s42255-026-01643-4
- Canonical
- link ↗
- Fetched
- 2026-10-30 MST
Cite this
APA
Koning, M., Kovynev, A., Fondevila, M.F., Ruhé, E.J.M., Mommersteeg, M.C., Ramakers, C.R.B., Hutten, B.A., Verwer, B.J., Vlug, M.S., Kuiper, T., Berg, M.W.V.D., Vrieze, A., Bizino, M.B., Beld, A.W.V.D., Berk, L., Boerlage, T.C.C., Augustijn, Q.J.J., Brouwer, W.P., Chen, W.J., & Cahen, D.L. (2026). Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial. <em>Nature Metabolism</em>. https://doi.org/10.1038/s42255-026-01643-4
Vancouver
Koning M, Kovynev A, Fondevila MF, Ruhé EJM, Mommersteeg MC, Ramakers CRB, et al. Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial. Nature Metabolism. 2026. doi:10.1038/s42255-026-01643-4.
BibTeX
@article{mijra2026Senoly,
title = {Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial},
author = {Mijra Koning and Artemiy Kovynev and Marcos F. Fondevila and Eliza J. M. Ruhé and Michiel C. Mommersteeg and Christian R. B. Ramakers and Barbara A. Hutten and Bart J. Verwer and Marije S. Vlug and Teaco Kuiper and Maarten W. Van Den Berg and Anne Vrieze and Maurice B. Bizino and Annewieke W. van den Beld and Luuk Berk and Thomas C. C. Boerlage and Quinten J. J. Augustijn and Willem Pieter Brouwer and Weena J. Chen and Djuna L. Cahen and Robert C. Verdonk and Wouter J. de Jonge and Sandjai Ramsoekh and Michail Doukas and Sanne Vermorgen},
journal = {Nature Metabolism},
year = {2026},
doi = {10.1038/s42255-026-01643-4},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Diabetes Care 2022
Preprint · OA
Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D)
F1000Research 2024
Open access · CC-BY
Protocol for a pilot clinical trial of the senolytic drug combination Dasatinib Plus Quercetin to mitigate age-related health and cognitive decline in mental disorders
F1000Research 2025
Open access · CC-BY
Protocol for a pilot clinical trial of the senolytic drug combination Dasatinib Plus Quercetin to mitigate age-related health and cognitive decline in mental disorders
Nature Communications 2023
Open access · CC-BY
NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease
Chinese Journal of Osteoporosis and Bone Mineral Research 2013
Citation only
The effect of age on the changes in bone mineral density and osteoporosis detection rates in men over fifty years
F1000Research 2024
Open access · CC-BY